Zhang X, et al. (2012) Neferine, an alkaloid ingredient in lotus seed embryo, inhibits proliferation of human osteosarcoma cells by promoting p38 MAPK-mediated p21 stabilization. Eur J Pharmacol 677, 47-54 22227330

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S130-p - p21Cip1 (human) ▲

Modsite: sGEQAEGsPGGPGDs SwissProt Entrez-Gene Orthologous residues p21Cip1 (human): S130‑p, p21Cip1 (mouse): S125‑p, p21Cip1 (rat): S130‑p, p21Cip1 (dog): S98‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  bone cancer, osteosarcoma Relevant cell lines - cell types - tissues:  MG63 (bone cell), Saos-2 (bone cell), U2OS (bone cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE P38A (mouse) activation of upstream enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes neferine increase SB203580 neferine inhibit treatment-induced increase siRNA neferine inhibit treatment-induced increase p38MAPK specific siRNA SP600125 neferine no effect upon treatment-induced increase siRNA no effect upon treatment-induced increase JNK specific siRNA Downstream Regulation Effect of modification (function):  protein stabilization